Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy.
Reads0
Chats0
TLDR
The clinical use of blinatumomab, a bispecific antibody that coordinates cytotoxic CD3+ T lymphocytes and CD19+ lymphoblasts, has resulted in improved outcomes in both relapsed/refractory and minimal residual disease-positive B-cell ALL.Abstract:
Several therapeutic advancements in the treatment of B-cell acute lymphoblastic leukemia (ALL) have surfaced in the past decade, primarily driven by an increased understanding of the immunopathobiology of this disease. The clinical use of blinatumomab, a bispecific antibody that coordinates cytotoxic CD3+ T lymphocytes and CD19+ lymphoblasts, has resulted in improved outcomes in both relapsed/refractory and minimal residual disease-positive B-cell ALL. Promising emerging data also demonstrate the efficacy of this agent in the frontline setting and in combination regimens. Uncertainty remains regarding the optimal sequencing and combination of blinatumomab with cytotoxic chemotherapy and other emerging agents. The pharmacology and clinical data on blinatumomab for adult B-cell ALL, both as monotherapy and in combinations, will be reviewed herein.read more
Citations
More filters
Journal ArticleDOI
Magnesium sensing via LFA-1 regulates CD8+ T cell effector function
Jonas Lötscher,Adrià-Arnau Martí I Líndez,Nicole Kirchhammer,Elisabetta Cribioli,Greta A Giordano,Marcel P. Trefny,Markus Lenz,Sacha I. Rothschild,Paolo Strati,Marco Künzli,Claudia. Lotter,Susanne H. Schenk,Philippe Dehio,Jordan Löliger,Ludivine C. Litzler,David Schreiner,Victoria Koch,Nicolas Page,Da-Youn Lee,Jasmin Grählert,Dmitry Kuzmin,Anne-Valérie Burgener,Doron Merkler,Miklos Pless,Maria L. Balmer,Walter Reith,Jörg Huwyler,Melita Irving,Carolyn G. King,Alfred Zippelius,Christoph Hess +30 more
TL;DR: In this article , the co-stimulatory cell-surface molecule LFA-1 requires magnesium to adopt its active conformation on CD8+ T cells, thereby augmenting calcium flux, signal transduction, metabolic reprogramming, immune synapse formation, and specific cytotoxicity.
Journal ArticleDOI
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors.
Jim Middelburg,Kristel Kemper,Patrick J. Engelberts,Aran F. Labrijn,Janine Schuurman,Thorbald van Hall +5 more
TL;DR: In this article, the authors provide a brief status update of the CD3-bispecific antibody therapy field and identify intrinsic hurdles in solid cancers, and describe potential combinatorial approaches to overcome these challenges in order to generate selective and more effective responses.
Journal ArticleDOI
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions
Marcus Unterrainer,Michael Ruzicka,Matthias P. Fabritius,Lena M. Mittlmeier,Michael Winkelmann,Johannes Rübenthaler,Matthias Brendel,Marion Subklewe,Michael von Bergwelt-Baildon,Jens Ricke,Wolfgang G. Kunz,Clemens C. Cyran +11 more
TL;DR: Current concepts of response assessment to immunotherapy are reviewed with particular emphasis on hybrid imaging with 18 F-FDG-PET/CT and positron emission tomography emerges as a comprehensive imaging modality by assessing (patho-)physiological processes such as glucose metabolism, which enables more comprehensive response assessment in oncological patients.
Journal ArticleDOI
CART Cell Toxicities: New Insight into Mechanisms and Management.
TL;DR: Findings in the mechanisms and management of CART cell toxicities are presented and new management and prevention strategies are developed.
Journal ArticleDOI
Recent updates for antibody therapy for acute lymphoblastic leukemia.
TL;DR: Compared with chemotherapy, the application of an antibody–drug conjugates (ADC) called inotuzumab ozogamicin in relapsed or refractory (R/R) CD22 + .
References
More filters
Journal ArticleDOI
Treatment of acute lymphoblastic leukemia.
Ching-Hon Pui,William E. Evans +1 more
TL;DR: This review considers recent advances in the treatment of ALL, emphasizing issues that need to be addressed if treatment outcome is to improve further.
Journal ArticleDOI
T cell activation.
TL;DR: This year marks the 25th anniversary of the first Annual Review of Immunology article to describe features of the T cell antigen receptor (TCR), with a description of the current state of the understanding of TCR signaling and a summary of recent findings.
Journal ArticleDOI
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop M. Kantarjian,Anthony S. Stein,Nicola Gökbuget,Adele K. Fielding,Andre C. Schuh,Josep-Maria Ribera,Andrew H. Wei,Hervé Dombret,Robin Foà,Renato Bassan,Onder Arslan,Miguel A. Sanz,Julie Bergeron,Fatih Demirkan,Ewa Lech-Maranda,Alessandro Rambaldi,Xavier Thomas,Heinz-August Horst,Monika Brüggemann,Wolfram Klapper,Brent L. Wood,Alex Fleishman,Dirk Nagorsen,Chris Holland,Zachary Zimmerman,Max S. Topp +25 more
TL;DR: Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy among adult patients with relapsed or refractory B‐cell precursor ALL, and remission rates within 12 weeks after treatment initiation were significantly higher.
Journal ArticleDOI
Cytokine release syndrome
Alexander Shimabukuro-Vornhagen,Philipp Gödel,Marion Subklewe,Hans Joachim Stemmler,Hans A. Schlößer,Max Schlaak,M. Kochanek,B. Böll,Michael von Bergwelt-Baildon +8 more
TL;DR: This review provides a comprehensive overview of the mechanisms underlying CRS pathophysiology, risk factors, clinical presentation, differential diagnoses, and prognostic factors and gives practical guidance to the management of the cytokine release syndrome.
Journal ArticleDOI
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Max S. Topp,Nicola Gökbuget,Anthony S. Stein,Gerhard Zugmaier,Susan O'Brien,Ralf C. Bargou,Hervé Dombret,Adele K. Fielding,Leonard T. Heffner,Richard A. Larson,Svenja Neumann,Robin Foà,Mark R. Litzow,Josep-Maria Ribera,Alessandro Rambaldi,Gary J. Schiller,Monika Brüggemann,Heinz A. Horst,Chris Holland,Catherine Jia,Tapan Maniar,Birgit Huber,Dirk Nagorsen,Stephen J. Forman,Hagop M. Kantarjian +24 more
TL;DR: Single-agent blinatumomab showed antileukaemia activity in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia characterised by negative prognostic factors.
Related Papers (5)
Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Blinatumomab in Pediatric Acute Lymphoblastic Leukemia-From Salvage to First Line Therapy (A Systematic Review).
Manon Queudeville,Martin Ebinger +1 more